Physician profile
Srinivas Munugoti
NPI 1538133301
$850.75
in general payments reported to CMS, 2019-2025
11 companies · $81.10 in 2025
The $81.10 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2021: $14.35 · 2022: $37.28 · 2023: $398 · 2024: $203 · 2025: $81.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $177.84 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $129.29 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $109.97 | 2023 | Optimizer |
| Boston Scientific Corporation | $102.66 | 2023 | Watchman Access System |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Scpharmaceuticals INC. | $68.82 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $58.33 | 2023-2025 | Camzyos, Eliquis |
| Philips North America LLC | $41.02 | 2022-2024 | (Ck4) Mcot |
| Abbott Laboratories | $24.91 | 2023 | Freestyle Libre 3 |
| Kiniksa Pharmaceuticals, LTD. | $24.54 | 2023 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $13.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Munugoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.